Los Angeles Capital Management
SPRY icon

Los Angeles Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Los Angeles Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18K Hold
147
– – ﹤0.01% 2289
2026
Q1 		$1.18K Sell
147
-65,599
-100% -$629K ﹤0.01% 2336
2025
Q4 		$567K Buy
+65,746
New +$639K ﹤0.01% 845
2024
Q3 		– Sell
-27,120
Closed -$231K – 1289
2024
Q2 		$231K Buy
+27,120
New +$241K ﹤0.01% 1096

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Los Angeles Capital Management's SPRY Position: Q2 2026 in Review

Los Angeles Capital Management held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 147 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

Los Angeles Capital Management first reported a position in SPRY in Q2 2024 and has held it in 4 quarters since. The position peaked at $567K in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Los Angeles Capital Management held 147 shares of ARS Pharmaceuticals worth $1.18K as of Q2 2026.
  • Los Angeles Capital Management left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2289 holding.
  • Los Angeles Capital Management first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 4 quarters since.
  • Los Angeles Capital Management's ARS Pharmaceuticals position peaked at $567K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.